Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

NCT01237457 is registered in ClinicalTrials.gov with Ebrahim S Delpassand as lead sponsor.

NCT NCT01237457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01237457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Lead sponsor
Ebrahim S Delpassand
Phase
Phase 2
Overall status
Completed
Start date
October 27, 2010
Completion date
July 25, 2017
Enrollment
143 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors